PMID- 23663037
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20130603
IS  - 1744-7623 (Electronic)
IS  - 1472-8214 (Linking)
VI  - 18
IP  - 2
DP  - 2013 Jun
TI  - Emerging drugs for prevention of graft failure after allogeneic hematopoietic 
      stem cell transplantation.
PG  - 173-92
LID - 10.1517/14728214.2013.798642 [doi]
AB  - INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is 
      the treatment of choice for many patients suffering from hematological 
      malignancies, severe hemoglobinopathies, bone marrow failures or severe primary 
      immunodeficiencies. Graft rejection/failure (GF) is a life-threatening 
      complication following allo-HSCT that is most commonly caused by the reactivity 
      of recipient T cells, natural killer (NK) cells or antibodies against donor 
      grafted hematopoietic cells. The increasing use of allo-HSCT following 
      reduced-intensity conditioning (RIC) and the increasing use of alternative donors 
      (unrelated cord blood and human leukocyte antigen (HLA)-mismatched donor) have 
      resulted in higher frequency of GF. AREAS COVERED: This review describes the 
      pathogenesis and current prevention and treatment of GF as well as agents in 
      development for GF prevention or treatment. EXPERT OPINION: The risk of GF may be 
      reduced in the future by optimizing the conditioning regimens and post-grafting 
      immunosuppression, increasing the number of hematopoietic stem cells (HSCs) 
      and/or immune cells transplanted, optimizing HSC homing and better detecting 
      patients at high risk of GF by searching for pre-transplant donor-specific 
      anti-HLA antibodies in patients given grafts from HLA-mismatched donors, or by 
      closely monitoring donor T- and/or NK-cell chimerism after allo-HSCT following 
      RIC.
FAU - Servais, Sophie
AU  - Servais S
AD  - University and CHU of Liege, Division of Hematology, Department of Medicine, CHU 
      Sart-Tilman, 4000 Liege, Belgium. F.Baron@ulg.ac.be
FAU - Beguin, Yves
AU  - Beguin Y
FAU - Baron, Frederic
AU  - Baron F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130510
PL  - England
TA  - Expert Opin Emerg Drugs
JT  - Expert opinion on emerging drugs
JID - 101135662
SB  - IM
MH  - Animals
MH  - Graft vs Host Disease/*prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Transplantation, Homologous
EDAT- 2013/05/15 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/05/14 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - 10.1517/14728214.2013.798642 [doi]
PST - ppublish
SO  - Expert Opin Emerg Drugs. 2013 Jun;18(2):173-92. doi: 
      10.1517/14728214.2013.798642. Epub 2013 May 10.